Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.
Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...